BriaCell subsidiary BriaPro reports $1.32M assets, $299,950 cash after sCD80 license acquisition

BriaCell Therapeutics subsidiary BriaPro reported interim results showing $1.32 million in total assets and completed an $846,532 sCD80 license acquisition funded by share issuance.

Key Highlights:

• Unaudited interim statements for period ended April 30, 2026 filed; total assets $1,321,744 and cash $299,950.
• Acquired exclusive sCD80 license on March 31, 2026 by issuing 23,972,589 shares, recorded as $846,532 intangible asset.
• Nine-month net loss $712,236; accumulated deficit $1,892,661 and negative working capital $1,937,495 as of April 30, 2026.
• BriaCell provided $300,000 cash advance and a credit facility up to $3,000,000 (5% interest) to support sCD80 R&D.
• Warrant liability revaluation produced $110,088 gain for nine months, reducing warrant liability to $71,855.

Original SEC Filing:

This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.